SEC Filing: Form 8-K
Current report
VYNE TherapeuticsRooted in Innovation
VYNE Therapeutics
Current report
Annual report [Section 13 and 15(d), not S-K Item 405]
Prospectuses and communications, business combinations
Current report
Draft Registration Statement
Statement of changes in beneficial ownership of securities